The estimated Net Worth of Diane L. Parks is at least $651 Tausend dollars as of 23 September 2019. Ms. Parks owns over 14,940 units of Kura Oncology Inc stock worth over $297,007 and over the last 5 years she sold KURA stock worth over $0. In addition, she makes $354,335 as Independent Director at Kura Oncology Inc.
Diane has made over 1 trades of the Kura Oncology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 14,940 units of KURA stock worth $13,894 on 23 September 2019.
The largest trade she's ever made was buying 14,940 units of Kura Oncology Inc stock on 23 September 2019 worth over $13,894. On average, Diane trades about 879 units every 0 days since 2019. As of 23 September 2019 she still owns at least 14,940 units of Kura Oncology Inc stock.
You can see the complete history of Ms. Parks stock trades at the bottom of the page.
Diane L. Parks serves as Independent Director of the Company. From February 2016 to July 2018, Ms. Parks served as Senior Vice President, Head of U.S. Commercial for Kite Pharma, Inc., a publicly-held biopharmaceutical company, which was acquired by Gilead Sciences, Inc., where she developed and executed the strategic plan for the commercial launch of Yescarta®, the first CAR-T therapy approved for large B-cell lymphoma. From October 2014 to October 2015, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics, Inc., a publicly-held biopharmaceutical company, which was acquired by AbbVie, Inc., where she was responsible for the marketing strategy and launch of Imbruvica®. From 2007 to 2014, she served as Vice President, Sales for Amgen, Inc., a publicly-held biotechnology company, where she successfully led the hospital and nephrology sales teams. From 1999 to 2002, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech, Inc., a publicly-held biotechnology company, which was acquired by F. Hoffmann-La Roche AG. She currently serves on the boards of Calliditas Therapeutics AB, a publicly-held biopharmaceutical company, Soligenix, Inc., a publicly-held biopharmaceutical company, and TriSalus Life Sciences (formerly Surefire Medical, Inc.), a privately-held medical device company. Ms. Parks earned an M.B.A. from Georgia State University and a B.S. from Kansas State University.
As the Independent Director of Kura Oncology Inc, the total compensation of Diane Parks at Kura Oncology Inc is $354,335. There are 11 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.
Diane Parks is 67, she's been the Independent Director of Kura Oncology Inc since 2019. There are 2 older and 19 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Diane's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson und Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: